BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2020 3:43:52 AM | Browse: 697 | Download: 986
 |
Received |
|
2020-01-26 14:03 |
|
Peer-Review Started |
|
2020-01-26 14:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-02-26 19:49 |
|
Revised |
|
2020-03-26 03:45 |
|
Second Decision |
|
2020-06-05 08:00 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-07 03:54 |
|
Articles in Press |
|
2020-06-07 03:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-06-16 21:43 |
|
Typeset the Manuscript |
|
2020-07-03 12:56 |
|
Publish the Manuscript Online |
|
2020-07-07 03:43 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ping Chen, Min Yu, Ji-Liang Zhang, Wei-Yong Chen, Li Zhu, Yue Song, Cheng-Yi Jiang and Shuang Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shuang Zhang, MD, PhD, Doctor, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu 610041, Sichuan Province, China. shuangscu@126.com |
| Key Words |
Pulmonary sarcomatoid carcinoma; Immunotherapy; Programmed death-ligand 1; Pembrolizumab; Radiotherapy; Case report |
| Core Tip |
This is a case report of a Programmed death-ligand 1 (PD-L1)-overexpressing pulmonary sarcomatoid carcinoma (PSC) patient with a good response to pembrolizumab, indicating that pembrolizumab is an important treatment for PSC patients with PD-L1 overexpression. In this case, the patient received low-dose radiotherapy before pembrolizumab, which suggests that the combination of radiotherapy and immunotherapy may elevate treatment efficacy. |
| Publish Date |
2020-07-07 03:43 |
| Citation |
Chen P, Yu M, Zhang JL, Chen WY, Zhu L, Song Y, Jiang CY, Zhang S. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(13): 2876-2884 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i13/2876.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i13.2876 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
